Donor immune cells after transplant for leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether giving donor immune cells earlier or later after a stem cell transplant helps prevent relapse in people with tough-to-treat leukemia or MDS. Participants must be in remission one month after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant from a donor (allogeneic transplant)
- You had acute myeloid leukemia (AML) or myelodysplastic syndrome with increased blasts (MDS-IB)
- Your disease did not go away or came back before the transplant
- Tests within a month after transplant showed no remaining cancer cells (MRD-negative)
- You do not have uncontrolled graft-versus-host disease (GVHD)
- You do not have severe infections or major heart, liver, kidney, or lung problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving extra immune cells (called DLI) before or after a stem cell transplant can help prevent or treat leukemia relapse. These cells come from the same family member who donated your transplant, and the study also asks the donor to do some exercise sessions beforehand.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.